Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib + SRS for KRAS G12C-mutated NSCLC With Brain Metastases
NCT06248606Phase 2Recruiting
- Start
- Aug 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adagrasib in non-small cell lung cancer (NSCLC). Primary endpoint: Intracranial disease control rate at 3 months. Started Aug 2024; status: recruiting.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06248606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06248606.